{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-013334","form_type":"8-K","ticker":"CTNM","cik":"0001855175","company_name":"Contineum Therapeutics, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.183849+00:00","generated_at":"2026-05-23T05:12:15.011891+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development","bullets":["Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.","He previously served as VP and Therapeutic Area Head for Inflammation at Gilead Sciences.","Company plans to start Phase 2 proof-of-concept trial in IPF in H2 2025.","Received time-based option for 260,000 shares vesting over 42 months and performance-based option for 26,000 shares.","Grants are inducement awards under Nasdaq Listing Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-013334","json":"https://secwatch.observer/filing/0001437749-25-013334.json","markdown":"https://secwatch.observer/filing/0001437749-25-013334.md","text":"https://secwatch.observer/filing/0001437749-25-013334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925013334/0001437749-25-013334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925013334/cont20250422_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:12:15.011891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}